Nasus Pharma Stock Forecast

Stock Price Forecast

The 3 analysts with 12-month price forecasts for Nasus Pharma stock have an average target of 19.67, with a low estimate of 18 and a high estimate of 22. The average target predicts an increase of 575.95% from the current stock price of 2.91.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$18	$19.67	$19	$22
Change	+518.56%	+575.95%	+552.92%	+656.01%

* Price targets were last updated on Mar 26, 2026.

Analyst Ratings

The average analyst rating for Nasus Pharma stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	1	1	1	1
Buy	1	1	2	2
Hold	0	0	0	0
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	2	2	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason N. Butler Citizens	Citizens	Buy Maintains $19 → $18	Buy	Maintains	$19 → $18	+518.56%	Mar 26, 2026
Jason Butler Citizens	Citizens	Buy Initiates $19	Buy	Initiates	$19	+552.92%	Dec 18, 2025
Yale Jen Laidlaw & Co.	Laidlaw & Co.	Strong Buy Initiates $22	Strong Buy	Initiates	$22	+656.01%	Sep 29, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.65

from -0.73

EPS Next Year

-1.49

from -1.65

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-
EPS	-0.25	-0.20	-0.22	-0.73	-1.65	-1.49
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-
No. Analysts	-	-	-	-	4	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-1.07	-1.19
Avg	-1.65	-1.49
Low	-2.18	-1.75

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.